Ropinirole News and Research

RSS

Groundbreaking study reveals most effective adjunctive drug for Parkinson's disease

The efficacy, tolerability, and safety of various anti-Parkinson's drugs.

23 Oct 2023

Parkinson's disease drug ropinirole is safe and tolerable for ALS patients, early clinical trial shows

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal motor neuron disease that causes people to gradually lose control of their muscles.

1 Jun 2023

Increase in out-of-pocket costs associated with lower adherence to neurologic medications

As out-of-pocket costs go up for drugs for the neurologic disorders Alzheimer's disease, peripheral neuropathy and Parkinson's disease, people are less likely to take the drugs as often as their doctors prescribed, according to a study funded by the American Academy of Neurology and published in the February 19, 2020, online issue of Neurology, the medical journal of the American Academy of Neurology.

19 Feb 2020

New study supports motor cortex 'excitability' as cause of restless legs syndrome

Johns Hopkins Medicine researchers say new experiments using magnetic pulse brain stimulation on people with moderate to severe restless legs syndrome have added to evidence that the condition is due to excitability and hyperarousal in the part of the brain's motor cortex responsible for leg movement.

29 Aug 2018

Impulse control disorders found to be more common in people taking Parkinson's drugs

Over time, half of the people taking certain drugs for Parkinson's disease may develop impulse control disorders such as compulsive gambling, shopping or eating, according to a study published in the June 20, 2018, online issue of Neurology®, the medical journal of the American Academy of Neurology.

20 Jun 2018

New drug may limit disease progression, provide better symptom relief to Parkinson's patients

Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

31 Jul 2017

Ethosomes may be effective carrier system for transdermal delivery

Ethosomes are ethanolic nanovesicles that possess abundant amount of ethanol in its core which provides fluidity to the lipid bilayers and thus by this effect, improves the delivery of molecules into the deep skin layers.

7 Oct 2016

Parkinson's disease medications could lead to impulse control disorders

Drugs commonly prescribed to treat Parkinson's disease have been linked to impulse control disorders such as pathological gambling, compulsive buying, hypersexuality and binge eating in some patients, report neurologists from Loyola Medicine and Loyola University Chicago Stritch School of Medicine.

6 Apr 2016

Non-ergot derived dopamine agonists may be safe for the heart

Non-ergot derived dopamine agonists used to treat Parkinson's disease may be safe for the heart, according to preliminary research presented at EuroEcho-Imaging 2014 by Dr Hilal Erken Pamukcu, cardiologist at Ankara Diskapi Education and Research Hospital in Turkey.

4 Dec 2014

Actavis receives FDA approval for Ropinirole ER Tablets

Actavis Group, an international generic pharmaceuticals company, today announced that it received US FDA approval of Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg and 12mg, a generic equivalent to GlaxoSmithKline's Requip XL.

19 May 2012

Parkinson's disease drugs may lead to impulse control disorders

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients.

25 Mar 2011

Dopamine agonists used in treatment of Parkinson's disease may lead to impulse control disorders

Mayo Clinic researchers found that dopamine agonists used in treating Parkinson's disease result in impulse control disorders in as many as 22 percent of patients.

24 Mar 2011

French guy says Parkinson’s drug induced gambling and gay sex addiction, tries to sue GSK for $610,000

GlaxoSmithKline is being sued this week by a French father-of-two, alleging the British pharmaceutical firm’s drug – Reqip (Ropirnirole) to treat Parkinson’s disease turned him into a gay sex and gambling addict. Parkinson’s disease is a seriously and progressively debilitating disease that leads to tremors, slowing of movements and ultimately total immobility.

1 Feb 2011

Study suggests treating RLS may improve sleep and quality of life in people with fibromyalgia

A study in the Oct. 15, 2010 issue of the Journal of Clinical Sleep Medicine found that adults with fibromyalgia had a much higher prevalence and risk of restless legs syndrome than healthy controls. The study suggests that treating RLS may improve sleep and quality of life in people with fibromyalgia.

15 Oct 2010

Jazz Pharmaceuticals second-quarter net product sales increase 49% to $39.5 million

Jazz Pharmaceuticals, Inc. announced financial results for the second quarter ended June 30, 2010 and updated financial guidance for 2010. The company's updated financial guidance reflects higher expected sales of XYREM® (sodium oxybate) and the effects of recent financing activities.

11 Aug 2010

NIH issues SBIR grant to Titan Pharmaceutical for PD treatment development

Titan Pharmaceuticals, Inc. today announced that the National Institutes of Health has awarded the company a grant under the Small Business Innovation Research program supporting the development of a long-term, non-fluctuating dopamine agonist treatment for Parkinson's disease. The first year award in the amount of $300,000 will be available to Titan starting August 1, 2010, and an additional $195,000 for the second year starting August 1, 2011 has been recommended subject to availability of funds and satisfactory progress of the project. The grant will be administered by the National Institute of Neurological Disorders and Stroke.

27 Jul 2010

Patients with advanced Parkinson's disease prefer dopamine agonists, shows review

Of the three main types of oral drugs commonly added to levodopa therapy for patients with advanced Parkinson's disease, one might be the most effective, according to a new review.

9 Jul 2010

Reducing DA dosage causes acute withdrawal symptoms in Parkinson's patients

New research has shown that reducing the dosage of dopamine agonist (DA) drugs, a mainstay treatment for Parkinson's disease (PD), sometimes causes acute withdrawal symptoms similar to those reported by cocaine addicts -- including anxiety, panic attacks, depression, sweating, nausea, generalized pain, fatigue, dizziness and drug cravings. These symptoms can be severe, and are not alleviated by other PD medications.

12 Jan 2010

Dopamine agonists trigger destructive behaviors

A new study conducted at Mayo Clinic reports that one in six patients receiving therapeutic doses of certain drugs for Parkinson's disease develops new-onset, potentially destructive behaviors, notably compulsive gambling or hypersexuality.

9 Apr 2009

Save money wih generics

Today, more than ever, consumers can opt for generic equivalents of brand-name medications at substantial cost savings.

10 Dec 2008